ArticleACS nano2014
Versatile RNA interference nanoplatform for systemic delivery of RNAs.
Article in ACS nano, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 4 citations in OpenAlex.
- Complexed hyaluronic acid-based nanoparticles in cancer therapy and diagnosis: Research trends by natural language processing.Heliyon · 2025Article
- Synthesis of tyramine bis(dipicolylamine), a versatile synthetic receptor scaffold for oxyanion recognition.Supramolecular chemistry · 2025Article
- Endosomal escape: A bottleneck for LNP-mediated therapeutics.Proceedings of the National Academy of Sciences of the United States of America · 2024Review
- Advances and Challenges of Stimuli-Responsive Nucleic Acids Delivery System in Gene Therapy.Pharmaceutics · 2023Review
- Advanced Strategies for Overcoming Endosomal/Lysosomal Barrier in Nanodrug Delivery.Research (Washington, D.C.) · 2023Review
- Preparation and application of calcium phosphate nanocarriers in drug delivery.Materials today. Bio · 2022Review
- Advancements in Polymeric Nanocarriers to Mediate Targeted Therapy against Triple-Negative Breast Cancer.Pharmaceutics · 2022Review
- Insights on the Dynamic Innovative Tumor Targeted-Nanoparticles-Based Drug Delivery Systems Activation Techniques.International journal of nanomedicine · 2022Review
- Multifunctional biomolecule nanostructures for cancer therapy.Nature reviews. Materials · 2021Review
- Nucleolin-Targeting AS1411 Aptamer-Modified Micelle for the Co-Delivery of Doxorubicin and miR-519c to Improve the Therapeutic Efficacy in Hepatocellular Carcinoma Treatment.International journal of nanomedicine · 2021Article
- Optimal scanning concentration of MR imaging for tumor-bearing nude mice with SPIO-shRNA molecular probe.Scientific reports · 2020Article
- Polymerized Selenium Nanoparticles for Folate-Receptor-Targeted Delivery of Anti-Luc-siRNA: Potential for Gene Silencing.Biomedicines · 2020Article
- Specific, Surface-Driven, and High-Affinity Interactions of Fluorescent Hyaluronan with PEGylated Nanomaterials.ACS applied materials & interfaces · 2020Article
- Enzyme-Responsive Nanoparticles for Anti-tumor Drug Delivery.Frontiers in chemistry · 2020Review
- Stimuli-responsive nanocarriers for drug delivery, tumor imaging, therapy and theranostics.Theranostics · 2020Review
- Rekindling RNAi Therapy: Materials Design Requirements for In Vivo siRNA Delivery.Advanced materials (Deerfield Beach, Fla.) · 2019Review
- Review of polysaccharide particle-based functional drug delivery.Carbohydrate polymers · 2019Review
- Homotypic Cell Membrane-Cloaked Biomimetic Nanocarrier for the Targeted Chemotherapy of Hepatocellular Carcinoma.Theranostics · 2019Article
- Metal-Organic Framework Nanoparticle-Based Biomineralization: A New Strategy toward Cancer Treatment.Theranostics · 2019Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
Development of nontoxic, tumor-targetable, and potent in vivo RNA delivery systems remains an arduous challenge for clinical application of RNAi therapeutics. Herein, we report a versatile RNAi nanoplatform based on tumor-targeted and pH-responsive nanoformulas (NFs). The NF was engineered by combination of an artificial RNA receptor, Zn(II)-DPA, with a tumor-targetable and drug-loadable hyaluronic acid nanoparticle, which was further modified with a calcium phosphate (CaP) coating by in situ mineralization. The NF can encapsulate small-molecule drugs within its hydrophobic inner core and strongly secure various RNA molecules (siRNAs, miRNAs, and oligonucleotides) by utilizing Zn(II)-DPA and a robust CaP coating. We substantiated the versatility of the RNAi nanoplatform by demonstrating effective delivery of siRNA and miRNA for gene silencing or miRNA replacement into different human types of cancer cells in vitro and into tumor-bearing mice in vivo by intravenous administration. The therapeutic potential of NFs coloaded with an anticancer drug doxorubicin (Dox) and multidrug resistance 1 gene target siRNA (siMDR) was also demonstrated in this study. NFs loaded with Dox and siMDR could successfully sensitize drug-resistant OVCAR8/ADR cells to Dox and suppress OVCAR8/ADR tumor cell proliferation in vitro and tumor growth in vivo. This gene/drug delivery system appears to be a highly effective nonviral method to deliver chemo- and RNAi therapeutics into host cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.